In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Singin' the CRO Blues

Executive Summary

The big three CROs--Quintiles, Parexel, & Covance have suffered contract cancellations, less-than-glowing earnings reports, and diving stock prices over the last 12 months. But, while the near-term continues to look fairly bleak, there's cause for hope on the horizon. CROs are increasingly seen as strategic partners, rather than as a means of handling overflow. And there's likely to be major opportunities for companies offering specialized services. One particularly promising area involves using the Internet to streamline R&D--for example, web-enabled clinical trials.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts